|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/15/20 Accelerate Diagnostics, Inc 8-K:2,9 1/13/20 12:2.2M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 33K 2: EX-99.1 Miscellaneous Exhibit HTML 14K 3: EX-99.2 Miscellaneous Exhibit HTML 29K 8: R1 Cover HTML 49K 9: XML IDEA XML File -- Filing Summary XML 12K 12: XML XBRL Instance -- tm203402d1_8k_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 6K 5: EX-101.LAB XBRL Labels -- axdx-20200113_lab XML 97K 6: EX-101.PRE XBRL Presentations -- axdx-20200113_pre XML 64K 4: EX-101.SCH XBRL Schema -- axdx-20200113 XSD 13K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 11: ZIP XBRL Zipped Folder -- 0001104659-20-004117-xbrl Zip 20K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) i January 13, 2020
i Accelerate Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
| i 001-31822 | i 84-1072256 | |
| (Commission File Number) | (IRS Employer Identification No.) |
| i 3950 South Country Club Road, i Suite 470, i Tucson, i Arizona | i 85714 | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| i Common Stock, $0.001 par value per share | i AXDX |
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On January 13, 2020, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the quarter ending December 31, 2019 and full-year 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.
| Item 7.01 | Regulation FD Disclosure. |
On January 15, 2020, the Company will make a presentation at the 2020 J.P. Morgan Healthcare Conference. A copy of the presentation, which includes revenue guidance for 2020 and information regarding the Company’s business strategy, is attached hereto as Exhibit 99.2 and is incorporated herein by reference in its entirety. The presentation also will be posted to the investor relations section of the Company’s website at: http://ir.axdx.com/.
In accordance with General Instruction B.2 for Form 8-K, the information in Items 2.02 and 7.01 of this Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit | |
| Number | Description |
| 99.1 | Press Release, dated January 13, 2020 |
| 99.2 | Accelerate Diagnostics Presentation for J.P. Morgan Healthcare Conference, dated January 15, 2020 |
| 104 | Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document) |
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ACCELERATE DIAGNOSTICS, INC. (Registrant) |
| Date: January 15, 2020 |
/s/ Steve Reichling |
| Steve Reichling | |
| Chief Financial Officer |
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/15/20 | |||
| For Period end: | 1/13/20 | |||
| 12/31/19 | 10-K, SD | |||
| List all Filings | ||||